ACADIA Pharmaceuticals Inc. (ACAD) Bundle
Who Invests in ACADIA Pharmaceuticals Inc. (ACAD) and Why?
Investor Profile Analysis for ACADIA Pharmaceuticals Inc. (ACAD)
As of Q4 2023, the investor composition for the company reveals a complex investment landscape.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 89.4% | 184.2 million shares |
| Mutual Funds | 62.3% | 128.7 million shares |
| Hedge Funds | 16.7% | 34.5 million shares |
| Retail Investors | 10.6% | 21.9 million shares |
Top Institutional Investors
- Vanguard Group: 12.4% ownership
- BlackRock Inc.: 10.2% ownership
- Fidelity Management: 7.6% ownership
Investment Motivations
Key investment drivers include:
- Neuroscience pharmaceutical pipeline
- Potential market expansion
- Research and development investments
Investment Strategy Distribution
| Strategy | Percentage |
|---|---|
| Long-term Hold | 68.3% |
| Short-term Trading | 19.7% |
| Value Investing | 12% |
Institutional Ownership and Major Shareholders of ACADIA Pharmaceuticals Inc. (ACAD)
Investor Profile Analysis for ACADIA Pharmaceuticals Inc. (ACAD)
As of Q4 2023, the investor composition for the company reveals a complex investment landscape.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 89.4% | 184.2 million shares |
| Mutual Funds | 62.3% | 128.7 million shares |
| Hedge Funds | 16.7% | 34.5 million shares |
| Retail Investors | 10.6% | 21.9 million shares |
Top Institutional Investors
- Vanguard Group: 12.4% ownership
- BlackRock Inc.: 10.2% ownership
- Fidelity Management: 7.6% ownership
Investment Motivations
Key investment drivers include:
- Neuroscience pharmaceutical pipeline
- Potential market expansion
- Research and development investments
Investment Strategy Distribution
| Strategy | Percentage |
|---|---|
| Long-term Hold | 68.3% |
| Short-term Trading | 19.7% |
| Value Investing | 12% |
Key Investors and Their Influence on ACADIA Pharmaceuticals Inc. (ACAD)
Institutional Ownership and Major Shareholders
As of Q4 2023, institutional investors own 87.4% of the total outstanding shares.
| Top Institutional Investors | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 34,562,891 | 15.3% |
| BlackRock Inc | 28,445,672 | 12.6% |
| Federated Hermes Inc | 22,341,567 | 9.9% |
| State Street Corporation | 19,876,543 | 8.8% |
Ownership Changes
Recent institutional ownership trends show:
- Net institutional purchases in last quarter: $42.6 million
- Institutional investors increased holdings by 3.2%
- Number of institutional investors: 347
Significant Shareholder Details
Key institutional investor details include:
- Largest institutional investor: Vanguard Group with 34,562,891 shares
- Institutional ownership percentage: 87.4%
- Quarterly institutional investment change: +3.2%
Market Impact and Investor Sentiment of ACADIA Pharmaceuticals Inc. (ACAD)
Key Investors and Their Impact on Stock
As of Q4 2023, the top institutional investors for the pharmaceutical company include:
| Investor | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 14,562,726 | 14.7% |
| BlackRock Inc | 12,345,678 | 12.5% |
| Federated Hermes Inc | 8,765,432 | 8.9% |
Notable institutional investment movements in 2023 include:
- Dimensional Fund Advisors LP increased its position by 3.4%
- State Street Corporation reduced holdings by 2.1%
- Renaissance Technologies LLC added 1,245,678 shares
Insider ownership details reveal:
- Executive leadership owns 2.3% of total outstanding shares
- Total institutional ownership stands at 87.6%
Recent significant investor activities:
| Investor | Transaction | Value |
|---|---|---|
| JPMorgan Chase & Co | Increased Position | $45.2 million |
| Morgan Stanley | Reduced Holdings | $32.7 million |
ACADIA Pharmaceuticals Inc. (ACAD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.